INVOKANA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Invokana, and when can generic versions of Invokana launch?
Invokana is a drug marketed by Janssen Pharms and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.
This drug has two hundred and sixty-eight patent family members in forty-seven countries.
The generic ingredient in INVOKANA is canagliflozin. There are twenty-one drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the canagliflozin profile page.
DrugPatentWatch® Generic Entry Outlook for Invokana
Invokana was eligible for patent challenges on March 29, 2017.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be May 11, 2031. This may change due to patent challenges or generic licensing.
There have been seventeen patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
There are five tentative approvals for the generic drug (canagliflozin), which indicates the potential for near-term generic launch.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for INVOKANA?
- What are the global sales for INVOKANA?
- What is Average Wholesale Price for INVOKANA?
Summary for INVOKANA
International Patents: | 268 |
US Patents: | 5 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 3 |
Raw Ingredient (Bulk) Api Vendors: | 128 |
Clinical Trials: | 23 |
Patent Applications: | 978 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for INVOKANA |
Drug Sales Revenues: | Drug sales revenues for INVOKANA |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for INVOKANA |
What excipients (inactive ingredients) are in INVOKANA? | INVOKANA excipients list |
DailyMed Link: | INVOKANA at DailyMed |
![INVOKANA drug patent expirations Drug patent expirations by year for INVOKANA](/p/graph/s/t/INVOKANA-patent-expirations.png)
![Drug Prices for INVOKANA](/p/graph/drug-price/INVOKANA.png)
![Drug Sales Revenue Trends for INVOKANA](/p/graph/drug-sales-revenues/INVOKANA.png)
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for INVOKANA
Generic Entry Date for INVOKANA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for INVOKANA
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Brigham and Women's Hospital | Phase 2 |
University of Colorado, Denver | Phase 2 |
Boston Medical Center | Phase 2 |
Pharmacology for INVOKANA
Drug Class | Sodium-Glucose Cotransporter 2 Inhibitor |
Mechanism of Action | P-Glycoprotein Inhibitors Sodium-Glucose Transporter 2 Inhibitors |
Paragraph IV (Patent) Challenges for INVOKANA
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
INVOKANA | Tablets | canagliflozin | 100 mg and 300 mg | 204042 | 10 | 2017-03-29 |
US Patents and Regulatory Information for INVOKANA
INVOKANA is protected by nineteen US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of INVOKANA is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting INVOKANA
Pharmaceutical formulations
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF TYPE 2 DIABETES MELLITUS WITH 300 MG CANAGLIFLOZIN PER DAY
Pharmaceutical formulations
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
Pharmaceutical formulations
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS WITH 300 MG CANAGLIFLOZIN PER DAY
Pharmaceutical formulations
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS WITH 100 MG CANAGLIFLOZIN PER DAY
Pharmaceutical formulations
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
Pharmaceutical formulations
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF TYPE 2 DIABETES MELLITUS WITH 100 MG CANAGLIFLOZIN PER DAY
Pharmaceutical formulations
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF TYPE 2 DIABETES MELLITUS
Pharmaceutical formulations
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS WITH 300 MG CANAGLIFLOZIN PER DAY
Pharmaceutical formulations
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS WITH 100 MG CANAGLIFLOZIN PER DAY
Crystalline form of 1-(.beta.-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
Crystalline form of 1-(.beta.-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
Crystalline form of 1-(.beta.-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF TYPE 2 DIABETES MELLITUS
Glucopyranoside compound
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Glucopyranoside compound
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF TYPE 2 DIABETES MELLITUS
Glucopyranoside compound
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
Glucopyranoside compound
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
Crystalline form of 1-(.beta.-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethy- l]benzene hemihydrate
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF TYPE 2 DIABETES MELLITUS
Crystalline form of 1-(.beta.-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethy- l]benzene hemihydrate
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
Crystalline form of 1-(.beta.-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethy- l]benzene hemihydrate
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Janssen Pharms | INVOKANA | canagliflozin | TABLET;ORAL | 204042-001 | Mar 29, 2013 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Janssen Pharms | INVOKANA | canagliflozin | TABLET;ORAL | 204042-002 | Mar 29, 2013 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Janssen Pharms | INVOKANA | canagliflozin | TABLET;ORAL | 204042-001 | Mar 29, 2013 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Janssen Pharms | INVOKANA | canagliflozin | TABLET;ORAL | 204042-002 | Mar 29, 2013 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Janssen Pharms | INVOKANA | canagliflozin | TABLET;ORAL | 204042-002 | Mar 29, 2013 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Janssen Pharms | INVOKANA | canagliflozin | TABLET;ORAL | 204042-001 | Mar 29, 2013 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for INVOKANA
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Janssen-Cilag International NV | Invokana | canagliflozin | EMEA/H/C/002649 Invokana is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes.For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1. |
Authorised | no | no | no | 2013-11-15 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for INVOKANA
When does loss-of-exclusivity occur for INVOKANA?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 1036
Patent: FORMULACIONES FARMACEUTICAS PARA TRATAR ENFERMEDADES RELACIONADAS CON EL TRANSPORTADOR DE GLUCOSA DEPENDIENTE DE SODIO
Estimated Expiration: ⤷ Sign Up
Australia
Patent: 11250909
Patent: Pharmaceutical formulations comprising 1 - (beta-D-glucopyranosyl) - 2 -thienylmethylbenzene derivatives as inhibitors of SGLT
Estimated Expiration: ⤷ Sign Up
Patent: 15207823
Patent: Pharmaceutical formulations comprising 1-(beta-D-glucopyranosyl)-2-thienylmethylbenzene derivatives as inhibitors of SGLT
Estimated Expiration: ⤷ Sign Up
Patent: 17210661
Patent: Pharmaceutical formulations comprising 1-(beta-D-glucopyranosyl)-2-thienylmethylbenzene derivatives as inhibitors of SGLT
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 2012028857
Patent: formulações farmacêuticas que compreendem derivados de 1-(beta-d-glucopiranosil)-2-tienil-metilbenzeno como inibidores de sglt
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 99204
Patent: FORMULATIONS PHARMACEUTIQUES COMPRENANT DES DERIVES DE 1-(BETA-D-GLUCOPYRANOSYL)-2-THIENYLMETHYLBENZENE COMME INHIBITEUR DE SGLT (PHARMACEUTICAL FORMULATIONS COMPRISING 1 - (BETA-D-GLUCOPYRANOSYL) - 2 -THIENYLMETHYLBENZENE DERIVATIVES AS INHIBITORS OF SGLT)
Estimated Expiration: ⤷ Sign Up
Chile
Patent: 12003162
Patent: Formulacion farmaceutica de administracion oral que comprende un compuesto derivado de 1-(beta-d-glucopiranosil)-3-(2-tienilmetil)benceno sustituido, un diluyente , un desintegrante, un aglutinante y un lubricante; composición farmaceutica; y metodo para tratar un trastorno mediado por transportadores de glucosa dependientes de sodio.
Estimated Expiration: ⤷ Sign Up
China
Patent: 2883726
Patent: Pharmaceutical formulations comprising 1-(beta-D-glucopyranosyl)-2 -thienylmethylbenzene derivatives as inhibitors of SGLT
Estimated Expiration: ⤷ Sign Up
Patent: 8354930
Patent: 包含1-(β-D-吡喃葡萄糖基)-2-噻吩基-甲基苯衍生物的药物制剂 (Pharmaceutical formulations comprising 1-(beta-D-glucopyranosyl)-2-thienylmethylbenzene derivatives)
Estimated Expiration: ⤷ Sign Up
Colombia
Patent: 30184
Patent: Formulaciones famacéuticas que comprenden derivados de 1 (beta-d-glucopiranosil)-2-tienil-metilbenceno como inhibidores de sglt
Estimated Expiration: ⤷ Sign Up
Costa Rica
Patent: 120626
Patent: Formulaciones farmacéuticas que comprenden derivados de 1-(beta- D-glucopiranosil)-2-tienilmetil]benceno como inhibidores de los transportadores de glucosa dependientes de sodio (SGLT)
Estimated Expiration: ⤷ Sign Up
Croatia
Patent: 0161231
Estimated Expiration: ⤷ Sign Up
Cyprus
Patent: 18093
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 68988
Estimated Expiration: ⤷ Sign Up
Ecuador
Patent: 12012290
Patent: FORMULACIONES FARMACÉUTICAS
Estimated Expiration: ⤷ Sign Up
Eurasian Patent Organization
Patent: 2365
Patent: ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(БЕТА-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ (PHARMACEUTICAL FORMULATIONS COMPRISING 1-(BETA-D-GLUCOPYRANOSYL)-2-THIENYLMETHYLBENZENE DERIVATIVES AS INHIBITORS OF SGLT)
Estimated Expiration: ⤷ Sign Up
Patent: 1291217
Patent: ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 68988
Patent: COMPOSITIONS PHARMACEUTIQUES COMPRENANT DES DERIVES DE 1-(BETA-D-GLUCOPYRANOSYL)-2-THIENYLMETHYLBENZENE UTILES EN TANT QU'INHIBITEURS DE SGLT (PHARMACEUTICAL FORMULATIONS COMPRISING 1-(BETA-D-GLUCOPYRANOSYL)-2-THIENYLMETHYLBENZENE DERIVATIVES AS INHIBITORS OF SGLT)
Estimated Expiration: ⤷ Sign Up
Guatemala
Patent: 1200303
Patent: FORMULACIONES FARMACÉUTICAS
Estimated Expiration: ⤷ Sign Up
Hong Kong
Patent: 59250
Patent: 包含1-(β-D-吡喃葡萄糖基)-2-噻吩基-甲基苯衍生物的藥物製劑 (PHARMACEUTICAL FORMULATIONS COMPRISING 1-(BETA-D-GLUCOPYRANOSYL)-2-THIENYLMETHYLBENZENE DERIVATIVES)
Estimated Expiration: ⤷ Sign Up
Hungary
Patent: 29853
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 2858
Patent: הרכבים רוקחיים המכילים תולדות 1-(בתא-d-גלוקופיראנוזיל)-2-תיאנילמתילבנזן כמעכבי sglt (Pharmaceutical formulations comprising 1-(beta-d-glucopyranosyl)-2-thienylmethylbenzene derivatives as inhibitors of sglt)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 27406
Estimated Expiration: ⤷ Sign Up
Patent: 13526534
Estimated Expiration: ⤷ Sign Up
Patent: 16147866
Patent: SGLTの阻害剤としての1−(β−D−グルコピラノシル)−2−チエニル−メチルベンゼン誘導体を含有する医薬製剤 (PHARMACEUTICAL FORMULATIONS COMPRISING 1-(β-D-GLUCOPYRANOSYL)-2-THIENYL-METHYLBENZENE DERIVATIVES AS SGLT INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Jordan
Patent: 77
Patent: صيغ صيدلانية تشمل مشتقات 1-(بيتا-D- غلوكوبيرانوسيل) -2-ثينيل ميثيل بنزين كمثبطات SGLT (PHARMACEUTICAL FORMULATIONS COMPRISING 1-(BETA-D-GLUCOPYRANOSYL)-2-THIENYLMETHYLBENZENE DERIVATIVES AS INHIBITORS OF SGLT)
Estimated Expiration: ⤷ Sign Up
Lithuania
Patent: 68988
Estimated Expiration: ⤷ Sign Up
Malaysia
Patent: 7718
Patent: PHARMACEUTICAL FORMULATIONS
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 9570
Patent: FORMULACIONES FARMACEUTICAS QUE COMPRENDEN DERIVADOS DE 1-(BETA-D-GLUCOPIRANOSIL)-2-TIENIL-METILBENCENO COMO INHIBIDORES DE TRANSPORTADORES DE GLUCOSA DEPENDIENTES DE SODIO. (PHARMACEUTICAL FORMULATIONS COMPRISING 1 - (BETA-D-GLUCOPYRANOSYL ) - 2 -THIENYLMETHYLBENZENE DERIVATIVES AS INHIBITORS OF SGLT.)
Estimated Expiration: ⤷ Sign Up
Patent: 12013090
Patent: FORMULACIONES FARMACEUTICAS QUE COMPRENDEN DERIVADOS DE 1-(BETA-D-GLUCOPIRANOSIL)-2-TIENIL-METILBENCENO COMO INHIBIDORES DE TRANSPORTADORES DE GLUCOSA DEPENDIENTES DE SODIO. (PHARMACEUTICAL FORMULATIONS COMPRISING 1 - (BETA-D-GLUCOPYRANOSYL ) - 2 -THIENYLMETHYLBENZENE DERIVATIVES AS INHIBITORS OF SGLT.)
Estimated Expiration: ⤷ Sign Up
Montenegro
Patent: 531
Patent: FARMACEUTSKE FORMULACilE KOJE OBUHVATAJU DERIVATIVE 1 - (BE TA- D- GLUKOPIRANOZ IL)-2- TIENILMETILBENZENA KAO SGLT INHIBITORE (PHARMACEUTICAL FORMULATIONS COMPRISING 1 - (BETA-D-GLUCOPYRANOSYL) - 2 -THIENYLMETHYLBENZENE DERIVATIVES AS INHIBITORS OF SGLT)
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 3128
Patent: Pharmaceutical formulations comprising 1 - (beta-d-glucopyranosyl) - 2 -thienylmethylbenzene derivatives as inhibitors of sglt
Estimated Expiration: ⤷ Sign Up
Nicaragua
Patent: 1200168
Patent: FORMULACIONES FARMACÉUTICAS
Estimated Expiration: ⤷ Sign Up
Peru
Patent: 130227
Patent: FORMULACIONES FARMACEUTICAS QUE COMPRENDEN DERIVADOS DE 1-(BETA-D-GLUCOPIRANOSIL)-2-TIENILMETILBENCENO COMO INHIBIDORES DE SGLT
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 68988
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 68988
Estimated Expiration: ⤷ Sign Up
San Marino
Patent: 01600338
Patent: FORMULAZIONI FARMACEUTICHE COMPRENDENTI DERIVATI DI1-(BETA-D- GLUCOPIRANOSIL)-
2-TIENILMETILBENZENE COME INIBITORI DI SGLT
Estimated Expiration: ⤷ Sign Up
Serbia
Patent: 202
Patent: FARMACEUTSKE FORMULACIJE KOJE OBUHVATAJU DERIVATE 1-(BETA-D-GLUKOPIRANOZIL)-2-TIENILMETILBENZENA KAO SGLT INHIBITORE (PHARMACEUTICAL FORMULATIONS COMPRISING 1-(BETA-D-GLUCOPYRANOSYL)-2-THIENYLMETHYLBENZENE DERIVATIVES AS INHIBITORS OF SGLT)
Estimated Expiration: ⤷ Sign Up
Singapore
Patent: 5525
Patent: PHARMACEUTICAL FORMULATIONS COMPRISING 1 - (BETA-D-GLUCOPYRANOSYL) - 2 -THIENYLMETHYLBENZENE DERIVATIVES AS INHIBITORS OF SGLT
Estimated Expiration: ⤷ Sign Up
Patent: 201506114U
Patent: PHARMACEUTICAL FORMULATIONS COMPRISING 1 - (BETA-D-GLUCOPYRANOSYL) - 2 -THIENYLMETHYLBENZENE DERIVATIVES AS INHIBITORS OF SGLT
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 68988
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 1931209
Estimated Expiration: ⤷ Sign Up
Patent: 130062947
Patent: PHARMACEUTICAL FORMULATIONS COMPRISING 1-(BETA-D-GLUCOPYRANOSYL)-2-THIENYL-METHYLBENZENE DERIVATIVES AS INHIBITORS OF SGLT
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 96291
Estimated Expiration: ⤷ Sign Up
Taiwan
Patent: 99360
Estimated Expiration: ⤷ Sign Up
Patent: 1206447
Patent: Pharmaceutical formulations
Estimated Expiration: ⤷ Sign Up
Ukraine
Patent: 0207
Patent: ФАРМАЦЕВТИЧНА ТАБЛЕТКА, ЯКА МІСТИТЬ 1-(β-D-ГЛЮКОПІРАНОЗИЛ)-4-МЕТИЛ-3-[5-(4-ФТОРФЕНІЛ)-2-ТІЄНІЛМЕТИЛ]БЕНЗОЛ ЯК ІНГІБІТОР НАТРІЙЗАЛЕЖНОГО ПЕРЕНОСНИКА ГЛЮКОЗИ (НЗПГ) (PHARMACEUTICAL PILL THAT CONTAINS 1- (-D- HLYUKOPIRANOZYL) -4-METHYL -3- [5- (4-FLUOROPHENYL) -2 INHIBITORS TIYENILMETYL BENZOL NATRIYDEPENDENT TRANSPORTER OF GLUCOSE (NZPH))
Estimated Expiration: ⤷ Sign Up
Uruguay
Patent: 380
Patent: FORMULACIONES FARMACÉUTICAS QUE CONTIENEN DERIVADOS DE 1-(B(BETA)-D-GLUCOPIRANOSILO) Y SUS USOS
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering INVOKANA around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Spain | 2649737 | ⤷ Sign Up | |
Eurasian Patent Organization | 009768 | ЗАМЕЩЕННЫЕ КОНДЕНСИРОВАННЫЕ ГЕТЕРОЦИКЛИЧЕСКИЕ С-ГЛИКОЗИДЫ (SUBSTITUTED FUSED HETEROCYCLIC C-GLYCOSIDES) | ⤷ Sign Up |
Japan | 2007518683 | ⤷ Sign Up | |
South Korea | 20060057589 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDENT TRANSPORTER | ⤷ Sign Up |
Hong Kong | 1259250 | 包含1-(β-D-吡喃葡萄糖基)-2-噻吩基-甲基苯衍生物的藥物製劑 (PHARMACEUTICAL FORMULATIONS COMPRISING 1-(BETA-D-GLUCOPYRANOSYL)-2-THIENYLMETHYLBENZENE DERIVATIVES) | ⤷ Sign Up |
Netherlands | 300670 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for INVOKANA
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1651658 | 92426 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: CANAGLIFLOZINE |
1651658 | 300670 | Netherlands | ⤷ Sign Up | PRODUCT NAME: CANAGLIFLOZINE; REGISTRATION NO/DATE: EU/1/13/884/001-008 20131119 |
1651658 | 1490027-8 | Sweden | ⤷ Sign Up | PERIOD OF VALIDITY (FROM - UNTIL): 20240731 - 20281118 |
1651658 | PA2014008,C1651658 | Lithuania | ⤷ Sign Up | PRODUCT NAME: CANAGLIFOZINUM; REGISTRATION NO/DATE: EU/1/13/884/001 - EU/1/13/884/004, 2013- 11-15 EU/1/13/884/005 - EU/1/13/884/008 20131115 |
1651658 | C 2014 017 | Romania | ⤷ Sign Up | PRODUCT NAME: CANAGLIFLOZIN; NATIONAL AUTHORISATION NUMBER: EU/1/13/884; DATE OF NATIONAL AUTHORISATION: 20131115; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/13/884; DATE OF FIRST AUTHORISATION IN EEA: 20131115 |
1651658 | CR 2014 00024 | Denmark | ⤷ Sign Up | PRODUCT NAME: CANAGLIFLOZIN; REG. NO/DATE: EU/1/13/884/001-008 20131119 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |